Foundation Medicine Inc (FMI)

24.35
0.10 0.41
NASDAQ : Health Care
Prev Close 24.45
Open 24.55
Day Low/High 24.15 / 24.70
52 Wk Low/High 13.34 / 33.31
Volume 77.12K
Avg Volume 196.70K
Exchange NASDAQ
Shares Outstanding 35.06M
Market Cap 855.43M
EPS -2.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Foundation Medicine Reports Preliminary 2016 Results

Foundation Medicine Reports Preliminary 2016 Results

Foundation Medicine (NASDAQ:FMI) today announced preliminary unaudited total revenue of approximately $28.

Proven Biopharma Executive And Commercial Leader, Troy Cox, Named As Chief Executive Officer Of Foundation Medicine. (Photo: Business Wire)

Proven Biopharma Executive And Commercial Leader, Troy Cox, Named As Chief Executive Officer Of Foundation Medicine. (Photo: Business Wire)

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that, as part of the succession of its executive leadership, the Board of Directors has appointed Troy Cox, a highly regarded global biopharma leader, as chief...

Foundation Medicine To Present At The 35th Annual J.P. Morgan Healthcare Conference

Foundation Medicine To Present At The 35th Annual J.P. Morgan Healthcare Conference

Foundation Medicine (NASDAQ:FMI) today announced that Michael J.

Foundation Medicine Enters Oversold Territory (FMI)

Foundation Medicine Enters Oversold Territory (FMI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Relative Strength Alert For Foundation Medicine

Relative Strength Alert For Foundation Medicine

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Flatiron Health And Foundation Medicine Unveil Powerful Oncology Information Resource To Advance Precision Medicine

Flatiron Health And Foundation Medicine Unveil Powerful Oncology Information Resource To Advance Precision Medicine

Flatiron Health and Foundation Medicine, Inc. (NASDAQ:FMI) today announced the launch of a clinico-genomic database designed to help researchers and biopharmaceutical partners accelerate the development of targeted...

Foundation Medicine Announces 2016 Third Quarter Results And Recent Highlights

Foundation Medicine Announces 2016 Third Quarter Results And Recent Highlights

Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its third quarter ended September 30, 2016.

Commit To Purchase Foundation Medicine At $20, Earn 18.7% Annualized Using Options

Commit To Purchase Foundation Medicine At $20, Earn 18.7% Annualized Using Options

Investors considering a purchase of Foundation Medicine Inc stock, but tentative about paying the going market price of $23.05/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $20 strike, which has a bid at the time of this writing of $2.05.

Foundation Medicine And Sarah Cannon Collaborate To Advance Personalized Medicine For Patients With Cancer

Foundation Medicine And Sarah Cannon Collaborate To Advance Personalized Medicine For Patients With Cancer

Foundation Medicine, Inc. (NASDAQ:FMI) and Sarah Cannon Research Institute (Sarah Cannon) today announced a collaboration focused on advancing personalized medicine utilizing molecular information for patients across...

Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty To Its Board Of Directors

Foundation Medicine Adds Life Sciences Leader Michael R. Dougherty To Its Board Of Directors

Foundation Medicine, Inc. (NASDAQ:FMI) today announced the election of Michael R.

Foundation Medicine Announces Timing For Third Quarter 2016 Financial Results And Conference Call

Foundation Medicine Announces Timing For Third Quarter 2016 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's third quarter ended September 30, 2016, will be released on Wednesday, November 2, 2016.

Foundation Medicine To Present At The Morgan Stanley Global Healthcare Conference

Foundation Medicine To Present At The Morgan Stanley Global Healthcare Conference

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that members of the company's management team will present at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016, at 5:25 p.

Foundation Medicine Adds New Immunotherapy Features To Its Market-Leading Products

Foundation Medicine Adds New Immunotherapy Features To Its Market-Leading Products

Foundation Medicine, Inc. (NASDAQ:FMI) today announced the addition of new clinical markers to its FoundationOne ® and FoundationOne ® Heme products, which are designed to enhance oncologists' insight into...

Foundation Medicine Announces 2016 Second Quarter Results And Recent Highlights

Foundation Medicine Announces 2016 Second Quarter Results And Recent Highlights

Foundation Medicine, Inc. (NASDAQ:FMI) today reported financial and operating results for its second quarter ended June 30, 2016.

FoundationOne® Accepted By FDA And CMS For Parallel Review And FDA Expedited Access Pathway

FoundationOne® Accepted By FDA And CMS For Parallel Review And FDA Expedited Access Pathway

Foundation Medicine, Inc. (NASDAQ: FMI) today announced that the U.

Commit To Buy Foundation Medicine At $15, Earn 9% Annualized Using Options

Commit To Buy Foundation Medicine At $15, Earn 9% Annualized Using Options

Investors eyeing a purchase of Foundation Medicine Inc shares, but tentative about paying the going market price of $23.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $15 strike, which has a bid at the time of this writing of 75 cents.

Foundation Medicine Announces Timing For Second Quarter 2016 Financial Results And Conference Call

Foundation Medicine Announces Timing For Second Quarter 2016 Financial Results And Conference Call

Foundation Medicine, Inc. (NASDAQ:FMI) today announced that financial results for the company's second quarter ended June 30, 2016, will be released on Tuesday, August 2, 2016.

Insider Trading Alert - EGLT, FMI And ICLD Traded By Insiders

Insider Trading Alert - EGLT, FMI And ICLD Traded By Insiders

Stocks with insider trader activity include EGLT, FMI and ICLD

Foundation Medicine (FMI) Is Strong On High Volume Today

Foundation Medicine (FMI) Is Strong On High Volume Today

Trade-Ideas LLC identified Foundation Medicine (FMI) as a strong on high relative volume candidate

Foundation Medicine Announces Release Of Molecular Information From FoundationCORE™ To The National Cancer Institute In Support Of The National Cancer Moonshot And Precision Medicine Initiatives

Foundation Medicine Announces Release Of Molecular Information From FoundationCORE™ To The National Cancer Institute In Support Of The National Cancer Moonshot And Precision Medicine Initiatives

Foundation Medicine, Inc. (NASDAQ:FMI) announced today that the company will release approximately 18,000 genomic profiles of adult cancers from its FoundationCORE ™ knowledgebase to the National Cancer...

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

Ever hear of space congestion, Bots or liquid biopsy? The phrases are part of a group of 21 investment buzzwords identified by Goldman Sachs in its annual buzzword report.

Insider Trading Alert - FMI, GNTX And CNBKA Traded By Insiders

Insider Trading Alert - FMI, GNTX And CNBKA Traded By Insiders

Stocks with insider trader activity include FMI, GNTX and CNBKA

New Data From Foundation Medicine And Collaborators Supports Use Of Comprehensive Genomic Profiling To Inform Therapeutic Choices In Advanced Breast Cancer

New Data From Foundation Medicine And Collaborators Supports Use Of Comprehensive Genomic Profiling To Inform Therapeutic Choices In Advanced Breast Cancer

Foundation Medicine, Inc. (NASDAQ:FMI) today presented new data in two presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016 that underscore the critical importance of integrating...

Data From A Study Utilizing FoundationOne® Heme Indicates Age-Associated Genomic Profiles In Acute Myeloid Leukemia

Data From A Study Utilizing FoundationOne® Heme Indicates Age-Associated Genomic Profiles In Acute Myeloid Leukemia

Foundation Medicine, Inc. (NASDAQ:FMI) today announced new data informed by comprehensive genomic profiling (CGP) using FoundationOne® Heme demonstrating the diverse and distinct genomic landscape of acute...

Foundation Medicine Presents New Data At ASCO 2016 Demonstrating That FoundationOne® May Help Predict Response To Cancer Immunotherapy Across A Variety Of Advanced Cancers

Foundation Medicine Presents New Data At ASCO 2016 Demonstrating That FoundationOne® May Help Predict Response To Cancer Immunotherapy Across A Variety Of Advanced Cancers

Foundation Medicine, Inc. (NASDAQ:FMI) and it collaborators presented data showing that higher tumor mutational burden, as estimated by comprehensive genomic profiling with FoundationOne ®, successfully...

FoundationOne® Identifies Patients With Advanced Lung Cancer Likely To Respond Or Develop Resistance To Certain RET Inhibitor Therapies

FoundationOne® Identifies Patients With Advanced Lung Cancer Likely To Respond Or Develop Resistance To Certain RET Inhibitor Therapies

Foundation Medicine, Inc. (NASDAQ:FMI) today announced new critical genomics data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016 demonstrating the clinical significance of comprehensive genomic...

Foundation Medicine And AstraZeneca Enter Strategic Collaboration For Lynparza Companion Diagnostic Assay

Foundation Medicine And AstraZeneca Enter Strategic Collaboration For Lynparza Companion Diagnostic Assay

Foundation Medicine, Inc. (NASDAQ:FMI) and AstraZeneca today announced that they have entered into a definitive agreement to develop a novel companion diagnostic assay for Lynparza (olaparib) to support its global...